Related Experiment Video
Updated: Mar 14, 2026
![Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58641.jpg&w=3840&q=50)
09:58
Semi-quantitative Assessment Using [18F]FDG Tracer in Patients with Severe Brain Injury
Published on: November 9, 2018
8.1K
Tardily accelerated neurologic deterioration in two-step thallium intoxication
Hiroshi Kuroda1, Yoshiyuki Mukai2, Shuhei Nishiyama1
1Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Summary
This case study details a 16-year-old experiencing two-step thallium poisoning, showing delayed neurological decline. The findings highlight cumulative neurotoxicity and progressive neuropathy without initial gastrointestinal or skin symptoms.
Area of Science:
- Toxicology
- Neurology
- Environmental Health
Background:
- Thallium intoxication is known from single exposures, but the clinical course of repeated or divisional ingestion remains poorly understood.
- Previous reports primarily documented acute, one-time thallium poisonings.
- Understanding diverse exposure scenarios is crucial for accurate diagnosis and management of thallium toxicity.
Observation:
- A 16-year-old presented with two distinct episodes of thallium sulfate ingestion over 52 days.
- Initial symptoms after the first ingestion included gastrointestinal distress, alopecia, followed by delayed neurological deficits (vision loss, myalgia, leg weakness).
- The second ingestion led to rapid, severe neurological deterioration without concurrent gastrointestinal or cutaneous symptoms, indicating cumulative effects.
Findings:
- Brain MRI revealed bilateral optic nerve atrophy, and nerve conduction studies showed severe peripheral neuropathy.
- Urine analysis confirmed elevated thallium levels, diagnosing thallium intoxication.
- Neurological symptoms largely improved over two years, though visual loss was persistent, suggesting long-term neurotoxic impact.
Implications:
- This case demonstrates that divisional thallium intoxication can cause delayed, accelerated neurological deterioration, primarily affecting the optic and peripheral nervous systems.
- The findings suggest thallium's cumulative neurotoxicity, with a longer elimination half-life in nervous tissue contributing to progressive damage.
- Clinicians should consider repeated or low-dose thallium exposure in cases of unexplained progressive neuropathy, even without typical acute symptoms.
Related Concept Videos
Anticholinesterase Agents: Poisoning and Treatment
1.9K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.9K
Toxidromes: Clinical Features
74
Toxidromes are specific patterns of symptoms resulting from toxic substance exposure. They help in the identification and treatment of poisoning. The symptoms of each toxidrome group indicate poisoning by a certain class of chemicals or drugs.1. Sympathomimetic: Stimulates the sympathetic nervous system. Symptoms include agitation, increased heart rate (HR), blood pressure (BP), respiratory rate (RR), temperature, and pupil size. Drugs like cocaine and amphetamines, along with tremors and...
74
Depolarizing Blockers: Pharmocokinetics
691
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
691
Myasthenia Gravis: Diagnostic Tests
3.0K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.0K

